**Dear editor**

The December 2014 issue of *Drug Design, Development and Therapy* included a review article by Santagostino entitled "A new recombinant factor VIII: from genetics to clinical use".[@b1-dddt-9-3817] The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).[@b1-dddt-9-3817] However, when reviewing licensed rFVIII products, Santagostino[@b1-dddt-9-3817] did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq^®^).[@b2-dddt-9-3817]--[@b4-dddt-9-3817] Nuwiq^®^ is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.[@b5-dddt-9-3817]

Santagostino[@b1-dddt-9-3817] described the gradual improvements made to rFVIII production/formulation and how these have coincided with the introduction of first-, second-, and third-generation rFVIII products, particularly in relation to the elimination of production-related additives from animal/human sources and viral removal/inactivation. These developments were summarized in [Table 1](#t1-dddt-9-3817){ref-type="table"} of the article,[@b1-dddt-9-3817] which is adapted here with an additional row providing the respective information for Nuwiq^®^ ([Table 1](#t1-dddt-9-3817){ref-type="table"}).

The Nuwiq^®^ production process is entirely free of additives of animal or human origin.[@b2-dddt-9-3817] In addition, the purification process for Nuwiq^®^ has incorporated technological advances into a multi-step process involving one centrifugation, two filtration, and five chromatography steps, including two dedicated virus clearance steps (solvent/detergent treatment and 20 nm nanofiltration).[@b2-dddt-9-3817]

Santagostino[@b1-dddt-9-3817] further described the protein structure of FVIII and the importance of post-translational modifications, importantly pointing out that "sulfation is required for full activity of FVIII" and that "glycosylation influences stability and modulates immunogenic properties". With respect to sulfation, Santagostino focused on sulfation of tyrosine 1680, which is a prerequisite for complex formation with VWF and influences the half-life of FVIII in the circulation.[@b1-dddt-9-3817] Table 3 of the article[@b1-dddt-9-3817] cited mass spectrometry data reported by Kannicht et al[@b4-dddt-9-3817] relating to non-sulfated Tyr1680 in hamster-derived rFVIII products, but did not report data for Nuwiq^®^ from the same article,[@b4-dddt-9-3817] which indicated that the amount of non-sulfated Tyr1680 present in Nuwiq^®^ was below the level of detection. In addition, Sandberg et al[@b3-dddt-9-3817] reported a higher VWF-binding affinity for Nuwiq^®^ compared with Advate^®^, Kogenate^®^ or ReFacto^®^. Table 3 of the review by Santagostino[@b1-dddt-9-3817] is adapted here with an additional row providing the respective information for Nuwiq^®^ ([Table 2](#t2-dddt-9-3817){ref-type="table"}).

With respect to glycosylation, Santagostino[@b1-dddt-9-3817] focused on the glycosylation patterns of turoctocog alfa (NovoEight^®^) and concluded that: "The oligosaccharide structures of the novel rFVIII \[Novo-Eight^®^\] and plasma-derived FVIII are very similar, with mainly small, quantitative differences, and heterogeneous glycosylation is present in both products."

Comparable glycosylation of Nuwiq^®^ and plasma-derived FVIII has also been reported.[@b4-dddt-9-3817] It is well documented that potentially antigenic non-human glycan epitopes, such as *N*-glycolylneuraminic acid (Neu5Gc) or Gal-α1-3Galβ1-(3)4GlcNAc-R (α-Gal), are present in recombinant products derived from hamster cells.[@b4-dddt-9-3817],[@b6-dddt-9-3817],[@b7-dddt-9-3817] Thus, a comparison of these epitopes in rFVIII products derived from hamster cells might have been of interest to your readers. As Nuwiq^®^ is produced in a human cell line, Neu5Gc or α-Gal are not present.[@b4-dddt-9-3817]

In summary, the Santagostino article[@b1-dddt-9-3817] was a welcome addition to the literature that provided a timely update on recent advances and developments in rFVIII treatment of hemophilia A. However, the omission of data for the new-generation human cell derived rFVIII, Nuwiq^®^, which have been summarized in this letter, was a major limitation of the article.[@b1-dddt-9-3817]
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###### 

Licensed recombinant factor VIII products

  Generation   Product (manufacturer)               FVIII                Cell line   Culture medium                  Stabilizer         Purification/viral inactivation
  ------------ ------------------------------------ -------------------- ----------- ------------------------------- ------------------ ---------------------------------
  First        Recombinate^®^ (Baxter BioScience)   Full-length          CHO         Bovine serum albumin            Human albumin      IAC/IEC
  Second       Kogenate^®^ FS (Bayer Healthcare)    Full-length          BHK         Human plasma protein solution   Sucrose            IAC/IEC/SD/UF
  Second       Helixate^®^ FS (CSL Behring)         Full-length          BHK         Human plasma protein solution   Sucrose            IAC/IEC/SD/UF
  Third        Advate^®^ (Baxter Healthcare)        Full-length          CHO         None                            Trehalose          IAC/IEC/SD
  Third        Xyntha/ReFacto^®^ AF (Pfizer)        B-domain-deleted     CHO         None                            Sucrose            IAC/IEC/SD/NF
  Third        Turoctocog alfa(Novo Nordisk)        B-domain-truncated   CHO         None                            Sucrose            IAC/IEC/SD/NF/SE
  New          Nuwiq^®^ (Octapharma AG)             B-domain-deleted     HEK         None                            Sucrose/arginine   IAC/IEC/SD/NF/SE

**Note:** Copyright © 2014. Dove Medical Press. Adapted from Santagostino E. A new recombinant factor VIII: from genetics to clinical use. *Drug Des Devel Ther*. 2014;8: 2507--2515.[@b1-dddt-9-3817] Additional data added for Nuwiq^®^.[@b2-dddt-9-3817]--[@b4-dddt-9-3817]

**Abbreviations:** FVIII, factor VIII; IAC, immunoaffinity chromatography; IEC, ion exchange chromatography; NF, nanofiltration; SD, solvent/detergent treatment; SE, size exclusion; UF, ultrafiltration.

###### 

Levels of non-sulfated tyrosine in Rfviii

  Product                                 Origin   Non-sulfated tyrosine 1680 (%)                           
  --------------------------------------- -------- -------------------------------- ----------------------- -----------------------
  Turoctocog alfa                         CHO      --                               --                      Below detection limit
  Full-length, third-generation rFVIII    CHO      2.6--16.7                        5.0--8.0                \>9.0
  Full-length, second-generation rFVIII   BHK      1--6.5                           1.5                     --
  BDD third-generation rFVIII             CHO      4.5--13.9                        4.0--5.0                --
  Simoctocog alfa, BDD                    HEK      --                               Below detection limit   *--*
  new-generation rFVIII                                                                                     

**Notes:** Levels of non-sulfated tyrosine in rFVIII included Advate^®^ (full-length third-generation rFVIII), Kogenate FS^®^ (full-length second-generation rFVIII), and Xyntha/ReFacto AF^®^ (B-domain-deleted third-generation rFVIII). The sulfated form dominated for all proteins, with the proportion of non-sulfated tyrosine 1680 being highest for some third-generation rFVIII products. A small peak for the non-sulfated isoform was also observed for second-generation rFVIII, while no non-sulfated species were detected for turoctocog alfa or Nuwiq^®^ (B-domain-deleted new-generation rFVIII). Below detection limit means negligible signal, \<1%, or \<0.5%, trace. Copyright © 2014. Dove Medical Press. Adapted from Santagostino E. A new recombinant factor VIII: from genetics to clinical use. *Drug Des Devel Ther*. 2014;8:2507--2515.[@b1-dddt-9-3817]

**Abbreviations:** BDD, B-domain-deleted; LC-MS/MS, liquid chromatography tandem mass spectrometry; rFVIII, recombinant factor VIII; MS-FT, mass spectrometry high resolution Fourier transform scan.
